Experimental cancer drug shows promise but study halted early
NCT ID NCT04659603
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 25 times
Summary
This study tested a drug called tusamitamab ravtansine in people with advanced breast or pancreatic cancer that has spread and has a specific marker (CEACAM5). The goal was to see if the drug could shrink tumors, either alone or with another chemotherapy. The study was stopped early, but researchers looked at safety and how well the drug worked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth Orlando Site Number : 8400001
Orlando, Florida, 32804, United States
-
Investigational Site Number : 0320001
Pergamino, Buenos Aires, B2700CPM, Argentina
-
Investigational Site Number : 0320002
Rosario, Santa Fe Province, 2000, Argentina
-
Investigational Site Number : 0320003
Capital Federal, Buenos Aires, 1012, Argentina
-
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, 8420383, Chile
-
Investigational Site Number : 1520002
Temuco, La Araucanía, 4800827, Chile
-
Investigational Site Number : 1520003
Santiago, Reg Metropolitana de Santiago, 7500921, Chile
-
Investigational Site Number : 1580001
Taichung, 40447, Taiwan
-
Investigational Site Number : 1580002
Tainan, 704, Taiwan
-
Investigational Site Number : 1580003
Taipei, 11217, Taiwan
-
Investigational Site Number : 3480003
Budapest, 1122, Hungary
-
Investigational Site Number : 4100001
Seoul, Seoul-teukbyeolsi, 03080, South Korea
-
Investigational Site Number : 4100002
Seoul, Seoul-teukbyeolsi, 06351, South Korea
-
Investigational Site Number : 4100003
Goyang-si, Gyeonggi-do, 10408, South Korea
-
Investigational Site Number : 5280001
Rotterdam, 3015 GD, Netherlands
-
Investigational Site Number : 5280002
Amsterdam, 1066 CX, Netherlands
-
Investigational Site Number : 5280003
Utrecht, 3584 CX, Netherlands
-
Investigational Site Number : 6430001
Moscow, 115478, Russia
-
Investigational Site Number : 6430002
Saint Petersburg, 197758, Russia
-
Investigational Site Number : 6430004
Pushkin, Saint- Petersburg, 196603, Russia
-
Investigational Site Number : 7240001
Barcelona, Barcelona [Barcelona], 08035, Spain
-
Investigational Site Number : 7240002
Majadahonda, Madrid, 28222, Spain
-
Investigational Site Number : 7240003
Madrid, Madrid, Comunidad de, 28046, Spain
-
Investigational Site Number : 7920001
Istanbul, 34722, Turkey (Türkiye)
-
Investigational Site Number : 7920002
Izmir, Turkey (Türkiye)
-
Investigational Site Number : 7920003
Adana, 01250, Turkey (Türkiye)
-
Investigational Site Number : 7920004
Ankara, 06100, Turkey (Türkiye)
-
Massachusetts General Hospital Site Number : 8400002
Boston, Massachusetts, 02114, United States
-
University of Wisconsin Site Number : 8400004
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.